Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...
Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback